AI-generated summary
The authors report a case study of one patient with cognitive decline who used home photobiomodulation with transcranial, body and intranasal light devices twice daily for 25 minutes per session. Montreal Cognitive Assessment and working memory scores improved, along with smell test results and quality of life, and no adverse effects were reported. The authors describe PBM as a possible approach for neurodegenerative disease, but a single patient cannot establish cause and effect.
- Who or what was studied
- One patient with cognitive decline and olfactory dysfunction
- Wavelengths
- 635, 810 nm
- Limits stated in the abstract
- The abstract describes a single case report, so the findings cannot be generalized and no control group was involved.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 635 nm, 810 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Cognitive decline, Case report, Photobiomodulation therapy, Near-infrared, Light-emitting diode, Montreal Cognitive Assessment. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.